BioTuesdays

Tag - Ed Arce

Assembly Biosciences

HCW starts Assembly Biosciences at neutral; PT $3.50

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10. Assembly is focused on developing treatments for chronic...

Axcella Logo

HCW starts Axcella Health at buy; PT $14

H.C. Wainwright initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $14 price target. The stock closed at $3.97 on July 2. Axcella Health is a clinical-stage biotechnology company pioneering a new...

HCW starts Metacrine at buy; PT $15

H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...

Arbutus Biopharma Logo

HCW starts Arbutus Biopharma at buy; PT $10

H.C. Wainwright launched coverage of Arbutus Biopharma (NASDAQ:ABUS) with a “buy” rating and price target of $10. The stock closed at $4.41 on Dec. 16. Arbutus is primarily focused on discovering, developing and...

Iterum Therapeutics Logo

HCW cuts Iterum Therapeutics PT to $9 from $14

H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...